Legend Biotech: Undervalued Leader In The CAR-T Race
Source: SeekingAlpha
2026-04-24 10:04:29 ET
So, since my November article , " Legend Biotech: Is Carvykti Changing Cancer Treatment Forever?, " Legend Biotech Corporation ( LEGN ) stock has traded down 14.9%, underperforming the iShares Biotechnology ETF ( IBB ) (1.5% return), as well as the S&P 500 ( SPY ) (5.1% return)....
Read the full article on Seeking Alpha
For further details see:
Legend Biotech: Undervalued Leader In The CAR-T Race
Legend Biotech Corporation
NASDAQ: LEGN
LEGN Trading
31.03% G/L:
$32.8618 Last:
8,520,944 Volume:
$25.37 Open:
LEGN Latest News
June 02, 2026 09:30:00 am
Legend Biotech Announces Late-Breaking Oral Presentation at EHA 2026 Showcasing Initial Phase 1 In Vivo CAR-T Data with LB2501 in Non-Hodgkin Lymphoma (NHL)
LEGN Stock Data
$3,309,357,827
166,569,786
N/A
63
N/A
Biotechnology & Life Sciences
Healthcare
US
Somerset
